Partnership with Centillion Introduces Groundbreaking Platform for On-Demand RNA Production, Reducing Time-to-Market for RNA Therapies with Continuous Flow Technology
" Quotient Sciences, in collaboration with Centillion, has installed the revolutionary Biofoundry-in-a-Box (BiaB™) at its Alnwick site, marking a new era in RNA drug manufacturing. This first-of-its-kind, GMP-compliant platform enables the continuous and flexible production of RNA-based therapies, including mRNA and saRNA, with rapid scale-up capabilities. The BiaB technology, designed to yield up to 1 million doses in 24 hours, will drive quicker transitions from pre-clinical to clinical stages, transforming RNA drug development pathways for unmet medical needs."
Quotient Sciences, a leading global drug development and manufacturing accelerator, announced the installation of Centillion’s™ proprietary Biofoundry-in-a-Box (BiaB™), the first multi-product GMP platform technology for end to end RNA manufacture.
BiaB is a modular, integrated, and automated RNA-micro factory which enables the end-to-end production of various RNA-based products, including messenger RNA (mRNA) and self-amplifying RNA (saRNA), and has the potential to significantly reduce the time it takes to bring RNA therapies to market.
The first of its kind, Centillion’s patented BiaB technology offers continuous flow-based manufacture and encapsulation of RNA, more flexibility with higher productivities at smaller footprints. It also enables larger quantities of RNA drug substance to be split and encapsulated in portions to create a series of RNA-LNPs for pre-clinical or clinical evaluation.
"We are excited to partner with Centillion Technology and install the world's first GMP Biofoundry-in-a-Box at our Alnwick site," said Paul Ryan, SVP and Head of Candidate Development at Quotient Sciences.
Gareth Jenkins, VP Science and Technology added: "This adoption of novel science and innovative technology demonstrates Quotient Sciences' commitment to accelerating drug development, with the potential to transform the development and manufacture of RNA-based drugs. Centillion’s technology combined with Quotient Science’s drug development capabilities is set to revolutionize the way RNA medicines are brought to market.
“This signals our entry into the development and acceleration of RNA-based drug products, with flexible, on-demand manufacture of RNA-based drug products and capacity for up to 1 million doses from the same machine in 24 hrs. Together with Centillion, we now look forward to working with our customers to support the pre-clinical to clinical transition of their RNA-based development candidates to bring new therapies to patients faster."
Prof. Harris Makatsoris, CEO at Centillion Technology Limited added: “The Biofoundry-in-a-Box is a significant advancement in RNA manufacturing. It is the key component of Centillion’s RNA-by-Design™ offering, for the delivery of regulatory ready, patient centric and equitable access to advanced therapies. The BiaB enables our mission of a robust response to unmet clinical needs for everyone, everywhere. The BiaB advantages over traditional methods of RNA manufacturing, include high throughput of high-quality pharmaceutical products, aligning with the rapid response needs of manufacturing accelerators as Quotient Sciences. It is efficient, flexible and cost-effective.
“Quotient Sciences is the first CDMO to successfully install and qualify the GMP Biofoundary-in-a-Box system. We’re delighted to be working with them to enable the development of new RNA-based therapies and accelerate the delivery of existing therapies to patients.”
Quotient Sciences has been collaborating with Centillion Technology since 2022 to guide and refine features of the Biofoundry-in-a-Box, supported by the Wellcome Leap R3 Program. Quotient Sciences worked with Centillion on operator usability and GMP guidance before the final system was delivered to Quotient Sciences' Alnwick site in July 2024 to be installed and commissioned.
